Synergy CHC Corp.
SNYRDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
Uritos®
Overactive Bladder
Odelepan
Alcohol Dependence
Remimazolam
General Anaesthesia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Uritos® | Phase 3 | Overactive Bladder | - | - |
Odelepan | Phase 3 | Alcohol Dependence | - | - |
Remimazolam | Phase 3 | General Anaesthesia | - | - |
Frequently asked questions
What is in Synergy CHC Corp.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Synergy CHC Corp.'s (SNYR) pipeline across Phase 3. Its lead program is Uritos® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Synergy CHC Corp.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Synergy CHC Corp. (SNYR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SNYR biotech catalysts?→
Add SNYR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Synergy CHC Corp.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.